In this review, the authors provide a comprehensive overview of the evolution of kidney graft preservation methods, detailing the transition from traditional SCS to more advanced technologies, such as HMP and HOPE. HMP has demonstrated advantages in reducing DGF and enhancing graft survival, with more recent studies advocating for the use of HMP across all donor types. LifePort Kidney Transporter was mentioned as part of the most widespread and commonly used HMP systems.

Other key points include:

• HMP significantly reduces the risk of DGF when compared to SCS, regardless of donor type
• 1-year and 3-year graft survival was superior with HMP compared to SCS
• Therapeutic Hypothermia was found to be inferior to HMP in DBDs regarding DGF
• Flow-driven devices require higher systolic pressure to maintain equal flow compared to pressure-driven devices such as the LKT, which produces endothelial damage and thus potentiating the risk of graft thrombosis

Evidence clearly situates HMP as superior compared to SCS, in both DGF and graft survival, independent of donor type.

Read the article here:https://www.mdpi.com/2075-1729/14/12/1647